Bile acids as signaling molecules — FXR and TGR5

This mechanistic review reframes bile acids — long thought of primarily as fat-digestion aids — as potent signaling molecules that actively govern the health of the intestinal lining. Two receptors sit at the center of this story: FXR, a nuclear receptor inside epithelial cells, and TGR5, a surface receptor found on intestinal stem cells. When bile acids activate these receptors, they trigger a cascade that tightens the junctions between gut cells, stimulates mucus production (MUC2), and can even drive regeneration of the epithelium itself. The review highlights a clinically important vulnerability: certain gut bacteria (Clostridium scindens and Clostridium hiranonis) are responsible for converting primary bile acids into secondary bile acids, which are the preferred activators of FXR and TGR5. Antibiotics readily wipe out these strains, collapsing secondary bile acid levels and — as a downstream consequence — weakening the gut barrier and reducing colonization resistance against pathogens like C. difficile. The FXR-MLCK pathway is specifically identified as the mechanistic route by which chenodeoxycholic acid (CDCA) reinforces tight junction integrity. Practically, the review points toward stool bile acid profiling (measuring the ratio of primary to secondary, and conjugated to free species) as a clinically meaningful readout, and flags ursodeoxycholic acid (UDCA) as an existing pharmaceutical with documented barrier-protective properties.

• TGR5 activation by bile acids in intestinal stem cells promotes epithelial regeneration, suggesting a direct role for the bile acid pool in controlling mucosal renewal capacity.
• Chenodeoxycholic acid (CDCA) protects intestinal barrier integrity specifically via the FXR-MLCK signaling pathway, increasing tight junction protein expression and limiting bacterial translocation.
• Antibiotic-mediated elimination of secondary bile acid-producing bacteria (Clostridium scindens, Clostridium hiranonis) reduces FXR/TGR5 activation, weakens barrier function, suppresses MUC2 stimulation, and lowers colonization resistance against C. difficile — linking antibiotic exposure to a measurable microbiome-bile acid-barrier axis failure.
• UDCA has documented barrier-protective effects and is available as a pharmaceutical, representing a potential intervention to restore FXR/TGR5 signaling when the endogenous bile acid pool is disrupted.
• Stool bile acid profiling (primary vs. secondary; conjugated vs. free) is proposed as a clinically actionable measurement to assess the functional status of this signaling axis.

This is a narrative mechanism review synthesizing published experimental and translational research on bile acid receptor biology in the intestinal epithelium; no original patient cohort or animal experiment was conducted by the authors. The review integrates molecular pathway data (FXR-MLCK, TGR5-stem cell signaling), microbiome-bile acid interaction studies, and available clinical evidence on UDCA. As a synthesis article, it does not report a sample size, intervention arm, or prospective follow-up period. Evidence quality across cited studies is heterogeneous, ranging from in vitro mechanistic work to observational microbiome data.

Because this is a mechanism review rather than a primary study, it cannot establish causality between antibiotic-induced bile acid depletion and clinical outcomes such as C. difficile infection rates or measurable barrier failure in humans. The proposed clinical utility of stool bile acid profiling lacks standardized reference ranges or validated cutoffs for intervention thresholds. The review does not address inter-individual variation in bile acid pool composition, host genetics (e.g., FXR polymorphisms), or diet — all of which modulate receptor activation independently of the microbiome. The next critical experiments would be interventional: randomized trials testing UDCA or microbiome-targeted repletion (e.g., spore-based secondary bile acid producers) in antibiotic-exposed patients, with stool bile acid profiles and barrier permeability as co-primary endpoints.

This review extends [§146], which demonstrates a specific therapeutic application of bile acid signaling — intermittent fasting elevating lithocholic acid (a secondary bile acid) to reprogram macrophages and alleviate ulcerative colitis via the same FXR/TGR5 axis described here, thereby providing in vivo proof-of-concept for the mechanistic framework this article lays out. It parallels [§155], which examines Saccharomyces boulardii's effects on intestinal barrier permeability through a distinct, non-bile-acid mechanism, offering a useful comparison point for how different upstream signals converge on tight junction regulation. The clinical vulnerability described here — antibiotic disruption of colonization resistance — also contextualizes [§153], a study on probiotic intervention in antibiotic-exposed infants, where restoration of a depleted microbial ecosystem (potentially including secondary bile acid producers) may underpin observed benefits. Finally, the review's emphasis on FXR-driven barrier protection and MUC2 stimulation parallels the mucus-layer focus seen in [§156] (Akkermansia muciniphila and mucosal integrity), underscoring a shared theme across the corpus that mucosal defense is multiply redundant and microbiome-dependent.

• Intermittent fasting alleviates ulcerative colitis via lithocholic acid-mediated macrophage reprogramming
  Directly applies the FXR/TGR5 bile acid signaling mechanisms reviewed here to a specific therapeutic context (intermittent fasting → lithocholic acid → macrophage reprogramming in UC), making it the closest mechanistic extension in the corpus.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Examines intestinal barrier function and tight junction integrity through a completely different upstream mechanism (S. boulardii), allowing readers to compare bile acid receptor-mediated vs. probiotic-mediated routes to the same endpoint.
• Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life
  Studies antibiotic-exposed infants given probiotic intervention — directly relevant to the review's clinical warning about antibiotics collapsing secondary bile acid production and barrier function in vulnerable populations.
• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Eubacterium rectale modulates gut inflammation via metabolic pathways (glutamine/NF-κB), providing a parallel example of how a single microbial species can drive mucosal outcomes through a metabolite-signaling axis, analogous to Clostridium scindens driving outcomes through secondary bile acids.
• Role of Akkermansia Muciniphila in Acne Vulgaris
  Akkermansia muciniphila's role in mucosal integrity and MUC2-related mucus biology parallels this review's finding that bile acid signaling stimulates MUC2, inviting comparison of two microbiome-dependent pathways that both protect the mucus layer.